The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL.
Gerhard Held
No relevant relationships to disclose
Niels Murawski
No relevant relationships to disclose
Marita Ziepert
No relevant relationships to disclose
Viola Poeschel
Other Remuneration - Roche
Carsten Zwick
No relevant relationships to disclose
Marcel Reiser
No relevant relationships to disclose
Sibylla Wilhelm
No relevant relationships to disclose
Tobias Gaska
No relevant relationships to disclose
Michael Heike
No relevant relationships to disclose
Joerg Schubert
No relevant relationships to disclose
Norbert Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Markus Loeffler
No relevant relationships to disclose
Christian Ruebe
No relevant relationships to disclose
Michael Pfreundschuh
Consultant or Advisory Role - Amgen; Merck; Onyx; Pfizer; Roche